Annual report [Section 13 and 15(d), not S-K Item 405]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of awards outstanding as of December 31, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares:
Year ended December 31,
2024 2023
Stock options (excluding exercisable penny stock options) 7,232,926  5,915,851 
Restricted 283,411  217,881 
Warrants 5,152,397  5,152,397 
Total 12,668,734  11,286,129 
Schedule of Significant Segment Expenses In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
(in thousands) Year ended December 31,
2024 2023
Employee expenses $ 9,971  $ 7,661 
Research and Development (excluding employee expenses):
Consulting and professional fees 3,148  2,479 
Clinical study expenses 736  — 
Product development 1,594  1,487 
Other* 981  620 
Total Research and development expense $ 6,459  $ 4,586 
General and administrative expense (excluding employee expenses):
General and administrative expenses 2,825  2,706 
Commercialization readiness expenses 632  360 
Total General and administrative expense 3,457  3,066 
Total operating expenses $ 19,887  $ 15,313 

* Other primarily includes patent and testing expenses for years ended December 31, 2024 and 2023.